HemoPalm is developing a POCT unit-use cartridge based blood analyzer, with full enterprise capabilities, which brings lab-quality analysis to the bedside in critical care situations such as the ICU, NICU and ER.

In 2014, the global POCT market for Blood Gases & Electrolytes was estimated to be $1.5 Billion.

Our go-to-market strategy is to evolve the HP in stages, as a modern enterprise solution for decentralized diagnostic needs in clearly defined clini-commercial application and markets.
— Lahav Gil

The HemoPalm IP integrates full CO-oximetry, measured through spectroscopy, which allows the user to measure total hemoglobin (Hb), Oxy-Hb, Deoxy-Hb, Met-Hb and carboxy-Hb, simultaneously with blood gases and electrolytes measured with electrochemical sensors, from the same blood sample on the same cartridge.  CO-oximetry has traditionally been performed using bench-top analyzers that are large, expensive, and usually located in central laboratories. There are many benefits to providing these blood tests near or at the point of care of patients, but these benefits are not realized due to the size and cost of the bench-top analyzers. In addition, the blood sample can be collected directly into the cartridge from a finger prick or, in the case of neonatals, a heel prick-prick, as an alternative to an arterial sample taken with a syringe, which makes the technology applicable in the markets outside of a main stream clinical setting like first responders, military, emerging economies and disaster relief.  These are all areas where central labs are simply not available.  In the hospital setting it allows rapid patient analysis in situations like emergency department triage.